Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920725 · ClinicalTrials.gov registry record · NA
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
A NA study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00920725 is a NA study that has completed, run by Rush University Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT00920725, a NA study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
Interventions
- DRUG Insulin (Aspart Insulin [Novolog], Regular Insulin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920725
The ClinicalTrials.gov registry entry for NCT00920725 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulin (Aspart Insulin [Novolog], Regular Insulin) is the first listed.
NCT00920725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00920725 about?
NCT00920725 is a clinical study titled "Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA". The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
What is the current status of trial NCT00920725?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2005-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00920725?
The interventions under investigation include: Insulin (Aspart Insulin [Novolog], Regular Insulin) (DRUG).
Who is sponsoring clinical trial NCT00920725?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.